Oxford BioMedica PLC
LSE:OXB
Oxford BioMedica PLC
LSE:OXB
Price:
642
GBX
1.42%
Market Closed
Market Cap:
£776m
Relative Value
The Relative Value of one
OXB
stock under the Base Case scenario is
hidden
GBX.
Compared to the current market price of 642 GBX,
Oxford BioMedica PLC
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OXB Relative Value
HIDDEN
Multiples Across Competitors
OXB Competitors Multiples
Oxford BioMedica PLC Competitors
Oxford BioMedica PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Oxford BioMedica PLC
LSE:OXB
|
776m GBP | 5.2 | -21.4 | -124.9 | -26.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.8B USD | 6.4 | 93.8 | 15.4 | 21.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.3 | 25.2 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 9.9 | 29.9 | 22.6 | 23.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.1B USD | 5.6 | 17.8 | 13.3 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.1B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.6 | 37.5 | 38.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
